Newly Approved Ibrance® (Palbociclib) from Pfizer Available Through Onco360

Company Again Selected as Limited Distribution Pharmacy Provider

LOUISVILLE, Ky.--()--Onco360, one of the nation’s largest independent providers of Oncology Pharmacy services, today announced that it has been selected by Pfizer, Inc. (“Pfizer”) as a limited distribution pharmacy network participant for Ibrance (palbociclib), Pfizer’s recently approved product for certain breast cancers. The addition of this medication marks another key product win for Onco360, which continues to grow its portfolio of limited distribution products.

On February 3, 2015, the U.S. Food and Drug Administration (FDA) approved Ibrance as a combination therapy for the treatment of certain types of breast cancer.

Ibrance is a kinase inhibitor indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease1.

Breast cancer is the second most common type of cancer among women in the United States. The National Cancer Institute estimates that 232,670 American women are living with advanced breast cancer and 40,000 died from the disease in 20142.

“In the last 12 months, Onco360 has been selected as a network pharmacy provider for 10 limited distribution products, further enhancing our portfolio and reflecting the success of our oncology pharmacy model,” said Paul Jardina, President and Chief Executive Officer of Onco360. “We are pleased to expand our relationship with Pfizer, and we are excited about the resonance and recognition the Onco360 oncology pharmacy model is garnering in the marketplace. As part of our commitment to cancer patients and their healthcare teams, Onco360 will continue to provide the most comprehensive pharmacy and clinical support services possible.”

Ibrance is immediately available for order through Onco360. Information on how to order can be obtained by visiting www.Onco360.com/Order. For more information about Onco360 please visit www.Onco360.com.

1. http://www.ibrancehcp.com/sites/g/files/g10019066/f/201502/USPI-Ibrance-palbociclib-capsules-Feb2015.pdf

2. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432871.htm

About Onco360® Oncology Pharmacy:

Onco360 (http://onco360.com) is one of the largest independent providers of Oncology Pharmacy services in the country. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. The Company’s clinical and dispensing model was developed specifically to meet the unique needs of oncology-treating physicians and their patients. Onco360 is advancing the continuum of oncology pharmaceutical care through patient advocacy, dispensing excellence, and the clinical experience and expertise that comes from its focus in oncology. Onco360 is headquartered in Louisville, KY and dispenses nationally through its network of JCAHO-accredited Oncology Pharmacies. PharMerica Corporation (NYSE:PMC), a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, made a significant strategic investment in Onco360 in December 2013.

Contacts

Media:
Onco360®
Amvrosios Ioannidis, 646-356-7705
amvrosiosi@Onco360.com

Contacts

Media:
Onco360®
Amvrosios Ioannidis, 646-356-7705
amvrosiosi@Onco360.com